Wings Therapeutics is a biotechnology company engaged in the development of therapies for patients suffering from Dystrophic Epidermolysis Bullosa (DEB), a rare genetic skin blistering disease. The company develops a pipeline of RNA therapies for several forms of DEB, conducts clinical trials as well as progresses other RNA molecules that are designed for other mutations that cause DEB.